Navigation Links
Vidaza receives positve opinion from European CHMP
Date:10/27/2008

The Aplastic Anemia & MDS International Foundation is pleased to inform patients that the European Committee for Medicinal Products for Human Use (CHMP) has awarded Vidaza (azacitidine) a positive opinion for the treatment of myelodysplastic syndromes (MDS) patients who are not eligible for stem cell transplants.

The CHMP's positive opinion is based on data from the AZA-001 trial, which demonstrated an overall, unprecedented survival benefit for higher-risk MDS patients. The positive opinion will be forwarded to the European Commission that generally follows the recommendation of the CHMP and issues final marketing approval.

"We are excited by Vidaza's positive CHMP opinion because there are few treatment options for patients in Europe with this disease," said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation, "Vidaza not only extends patients' lives, but also improves their quality of life. We are hopeful that Vidaza will receive marketing approval shortly and quickly be available for patients across Europe."

Myelodysplastic syndromes (MDS) occur when the bone marrow stem cells malfunction. This results in the production of too many defective blood cells and not enough normal cells. Diagnosis is made through blood tests and a bone marrow biopsy. Once diagnosed, treatment and evaluation should occur under the care of a hematologist or hematologists/oncologist. There are many subtypes of MDS classified according to how the disease manifests itself in the blood and marrow of the patient. Treatments include blood transfusions, growth factors, chemotherapy and bone marrow transplant.


'/>"/>

Contact: John Huber
huber@aamds.org
301-279-7202
Aplastic Anemia & MDS International Foundation
Source:Eurekalert

Page: 1

Related biology news :

1. The MDS Foundation supports the FDAs decision to expand vidaza label to include survival data
2. FDA approves Vidaza label expansion
3. Global Viral Forecasting Initiative receives $11M to implement pandemic early warning system
4. Penn State receives new NASA astrobiology grant
5. American College of Medical Genetics receives $13.5M NIH contract
6. Kount Receives Patent for Device Fingerprinting
7. L-1 Identity Solutions Receives $5.9 Million Drivers License Contract Expansion from the State of Mississippi
8. Wistar Institute researcher receives New Innovator award from NIH
9. CCNY receives $5 million NSF grant to establish center for nanostructure applications
10. NYU receives $490k NSF grant to promote women in the sciences
11. Childrens National researcher receives ACCP Distinguished Investigator Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
Breaking Biology Technology: